Literature DB >> 23183438

HIV-1 subtype is an independent predictor of reverse transcriptase mutation K65R in HIV-1 patients treated with combination antiretroviral therapy including tenofovir.

K Theys1, J Vercauteren, J Snoeck, M Zazzi, R J Camacho, C Torti, E Schülter, B Clotet, A Sönnerborg, A De Luca, Z Grossman, D Struck, A-M Vandamme, A B Abecasis.   

Abstract

Subtype-dependent selection of HIV-1 reverse transcriptase resistance mutation K65R was previously observed in cell culture and small clinical investigations. We compared K65R prevalence across subtypes A, B, C, F, G, and CRF02_AG separately in a cohort of 3,076 patients on combination therapy including tenofovir. K65R selection was significantly higher in HIV-1 subtype C. This could not be explained by clinical and demographic factors in multivariate analysis, suggesting subtype sequence-specific K65R pathways.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23183438      PMCID： PMC3553726          DOI： 10.1128/AAC.01668-12

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.

Authors:  Henry Sunpath; Baohua Wu; Michelle Gordon; Jane Hampton; Brent Johnson; Mahomed-Yunus S Moosa; Claudia Ordonez; Daniel R Kuritzkes; Vincent C Marconi
Journal:  AIDS       Date:  2012-08-24       Impact factor: 4.177

2.  Early virological failure after tenofovir + didanosine + efavirenz combination in HIV-positive patients upon starting antiretroviral therapy.

Authors:  Carlo Torti; Eugenia Quiros-Roldan; Mario Regazzi; Andrea Antinori; Andrea Patroni; Paola Villani; Valeria Tirelli; Giuliana Cologni; Daniela Zinzi; Sergio Lo Caputo; Paolo Perini; Giampiero Carosi
Journal:  Antivir Ther       Date:  2005

3.  K65R development among subtype C HIV-1-infected patients in tenofovir DF clinical trials.

Authors:  Michael D Miller; Nicolas Margot; Damian McColl; Andrew K Cheng
Journal:  AIDS       Date:  2007-01-11       Impact factor: 4.177

4.  The rise and fall of K65R in a Portuguese HIV-1 Drug Resistance database, despite continuously increasing use of tenofovir.

Authors:  Kristof Theys; Jurgen Vercauteren; Ana B Abecasis; Pieter Libin; Koen Deforche; Anne-Mieke Vandamme; Ricardo Camacho
Journal:  Infect Genet Evol       Date:  2008-11-06       Impact factor: 3.342

5.  Antiretroviral resistance in different HIV-1 subtypes: impact on therapy outcomes and resistance testing interpretation.

Authors:  Ricardo Jorge Camacho; Anne-Mieke Vandamme
Journal:  Curr Opin HIV AIDS       Date:  2007-03       Impact factor: 4.283

6.  Impact of HIV-1 viral subtype on disease progression and response to antiretroviral therapy.

Authors:  Philippa J Easterbrook; Mel Smith; Jane Mullen; Siobhan O'Shea; Ian Chrystie; Annemiek de Ruiter; Iain D Tatt; Anna Maria Geretti; Mark Zuckerman
Journal:  J Int AIDS Soc       Date:  2010-02-03       Impact factor: 5.396

7.  The K65R mutation in HIV-1 reverse transcriptase: genetic barriers, resistance profile and clinical implications.

Authors:  Bluma G Brenner; Dimitrios Coutsinos
Journal:  HIV Ther       Date:  2009-11-01

8.  K65R and Y181C are less prevalent in HAART-experienced HIV-1 subtype A patients.

Authors:  Ravindra K Gupta; Ian L Chrystie; Siobhan O'Shea; Jane E Mullen; Ranjababu Kulasegaram; Cheuk Y W Tong
Journal:  AIDS       Date:  2005-11-04       Impact factor: 4.177

9.  Factors associated with the emergence of K65R in patients with HIV-1 infection treated with combination antiretroviral therapy containing tenofovir.

Authors:  Viktor von Wyl; Sabine Yerly; Jürg Böni; Philippe Bürgisser; Thomas Klimkait; Manuel Battegay; Enos Bernasconi; Matthias Cavassini; Hansjakob Furrer; Bernard Hirschel; Pietro L Vernazza; Martin Rickenbach; Bruno Ledergerber; Huldrych F Günthard
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

10.  The risks and incidence of K65R and L74V mutations and subsequent virologic responses.

Authors:  Laura Waters; Mark Nelson; Sundhiya Mandalia; Mark Bower; Tom Powles; Brian Gazzard; Justin Stebbing
Journal:  Clin Infect Dis       Date:  2008-01-01       Impact factor: 9.079
View more
  16 in total

1.  An Evolutionary Model-Based Approach To Quantify the Genetic Barrier to Drug Resistance in Fast-Evolving Viruses and Its Application to HIV-1 Subtypes and Integrase Inhibitors.

Authors:  Kristof Theys; Pieter J K Libin; Kristel Van Laethem; Ana B Abecasis
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

Review 2.  Recent findings on the mechanisms involved in tenofovir resistance.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Antivir Chem Chemother       Date:  2014-12-16

3.  Basis for early and preferential selection of the E138K mutation in HIV-1 reverse transcriptase.

Authors:  Matthew McCallum; Maureen Oliveira; Ruxandra-Ilinca Ibanescu; Victor G Kramer; Daniela Moisi; Eugene L Asahchop; Bluma G Brenner; P Richard Harrigan; Hongtao Xu; Mark A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  2013-07-15       Impact factor: 5.191

4.  Analysis of a local HIV-1 epidemic in portugal highlights established transmission of non-B and non-G subtypes.

Authors:  Alexandre Carvalho; Patrício Costa; Vera Triunfante; Fernando Branca; Fernando Rodrigues; Catarina L Santos; Margarida Correia-Neves; Margarida Saraiva; Henrique Lecour; António G Castro; Jorge Pedrosa; Nuno S Osório
Journal:  J Clin Microbiol       Date:  2015-02-18       Impact factor: 5.948

5.  Resistance to tenofovir-based regimens during treatment failure of subtype C HIV-1 in South Africa.

Authors:  Christopher J Hoffmann; Johanna Ledwaba; Jin-Fen Li; Victoria Johnston; Gillian Hunt; Katherine L Fielding; Richard E Chaisson; Gavin J Churchyard; Alison D Grant; Jeffrey A Johnson; Salome Charalambous; Lynn Morris
Journal:  Antivir Ther       Date:  2013-06-10

6.  High-levels of acquired drug resistance in adult patients failing first-line antiretroviral therapy in a rural HIV treatment programme in KwaZulu-Natal, South Africa.

Authors:  Justen Manasa; Richard J Lessells; Andrew Skingsley; Kevindra K Naidu; Marie-Louise Newell; Nuala McGrath; Tulio de Oliveira
Journal:  PLoS One       Date:  2013-08-21       Impact factor: 3.240

7.  High prevalence of the K65R mutation in HIV-1 subtype C infected patients failing tenofovir-based first-line regimens in South Africa.

Authors:  Lindiwe Skhosana; Kim Steegen; Michelle Bronze; Azwidowi Lukhwareni; Esrom Letsoalo; Maria A Papathanasopoulos; Sergio C Carmona; Wendy S Stevens
Journal:  PLoS One       Date:  2015-02-06       Impact factor: 3.240

8.  COMET: adaptive context-based modeling for ultrafast HIV-1 subtype identification.

Authors:  Daniel Struck; Glenn Lawyer; Anne-Marie Ternes; Jean-Claude Schmit; Danielle Perez Bercoff
Journal:  Nucleic Acids Res       Date:  2014-08-12       Impact factor: 16.971

9.  Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.

Authors:  Katherine Brooks; Lameck Diero; Allison DeLong; Maya Balamane; Marissa Reitsma; Emmanuel Kemboi; Millicent Orido; Wilfred Emonyi; Mia Coetzer; Joseph Hogan; Rami Kantor
Journal:  J Int AIDS Soc       Date:  2016-05-25       Impact factor: 5.396

Review 10.  HIV-1 drug resistance and resistance testing.

Authors:  Dana S Clutter; Michael R Jordan; Silvia Bertagnolio; Robert W Shafer
Journal:  Infect Genet Evol       Date:  2016-08-29       Impact factor: 3.342
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.